Abstract
Background: The present study was designed to evaluate the efficacy and safety of a combination of helical tomotherapy (HT) or intensity-modulated radiotherapy (IMRT) and EGFR (epidermal growth factor receptor) inhibitor (Cetuximab or Nimotuzumab) with or without chemotherapy in patients with locally advanced hypopharyngeal carcinoma.
Patients and Methods: The retrospective study included forty-six patients (12 stage III and 34 stage IV) with locally advanced hypopharyngeal cancer. Among them, 20 were treated with induction chemotherapy with docetaxel and cisplatin (TP) followed by concurrent chemoradiotherapy with cisplatin and EGFR inhibitor, 13 received concurrent chemoradiotherapy with cisplatin and EGFR inhibitor, and 13 were treated with concurrent radiotherapy plus EGFR inhibitor. HT and IMRT were performed in 33 and 13 patients, respectively. Side effects were evaluated with the established CTCAE (Common Terminology Criteria for Adverse Events) 3.0 criteria.
Results: The median follow-up time was 39.4 months (range 3-69 months). All patients completed the planned RT without any treatment breaks. The 3-year local control survival, disease-free survival, overall survival, and laryngeal preservation survival rates were 66.8%, 59.0%, 68.9%, and 86.7%, respectively. The most common grade 3 or higher side effect was oropharyngeal mucositis. One patient required dilatation of a pharyngeal stricture 18 months after treatment. No patient required percutaneous gastrostomy and tracheostomy tube.
Conclusion: The treatment with EGFR inhibitor in combination with non-surgical combined modality in patients with hypopharyngeal carcinoma was well tolerated and resulted in encouraging laryngeal preservation survival rate. HT or IMRT, EGFR inhibitor, and effective management of severe oropharyngeal mucositis contributed to the positive outcomes.
Keywords: EGFR inhibitor, helical tomotherapy, intensity-modulated radiotherapy, laryngeal organ preservation, locally advanced hypopharyngeal carcinoma, non-surgical combined modality.
Current Cancer Drug Targets
Title:Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Volume: 14 Issue: 6
Author(s): Xinxin Zhang, Jailing Wang, Wenming Wu, Mingbo Liu, Feifang Zhao, Lei Du, Deliang Huang, Shiming Yang and Lin Ma
Affiliation:
Keywords: EGFR inhibitor, helical tomotherapy, intensity-modulated radiotherapy, laryngeal organ preservation, locally advanced hypopharyngeal carcinoma, non-surgical combined modality.
Abstract: Background: The present study was designed to evaluate the efficacy and safety of a combination of helical tomotherapy (HT) or intensity-modulated radiotherapy (IMRT) and EGFR (epidermal growth factor receptor) inhibitor (Cetuximab or Nimotuzumab) with or without chemotherapy in patients with locally advanced hypopharyngeal carcinoma.
Patients and Methods: The retrospective study included forty-six patients (12 stage III and 34 stage IV) with locally advanced hypopharyngeal cancer. Among them, 20 were treated with induction chemotherapy with docetaxel and cisplatin (TP) followed by concurrent chemoradiotherapy with cisplatin and EGFR inhibitor, 13 received concurrent chemoradiotherapy with cisplatin and EGFR inhibitor, and 13 were treated with concurrent radiotherapy plus EGFR inhibitor. HT and IMRT were performed in 33 and 13 patients, respectively. Side effects were evaluated with the established CTCAE (Common Terminology Criteria for Adverse Events) 3.0 criteria.
Results: The median follow-up time was 39.4 months (range 3-69 months). All patients completed the planned RT without any treatment breaks. The 3-year local control survival, disease-free survival, overall survival, and laryngeal preservation survival rates were 66.8%, 59.0%, 68.9%, and 86.7%, respectively. The most common grade 3 or higher side effect was oropharyngeal mucositis. One patient required dilatation of a pharyngeal stricture 18 months after treatment. No patient required percutaneous gastrostomy and tracheostomy tube.
Conclusion: The treatment with EGFR inhibitor in combination with non-surgical combined modality in patients with hypopharyngeal carcinoma was well tolerated and resulted in encouraging laryngeal preservation survival rate. HT or IMRT, EGFR inhibitor, and effective management of severe oropharyngeal mucositis contributed to the positive outcomes.
Export Options
About this article
Cite this article as:
Zhang Xinxin, Wang Jailing, Wu Wenming, Liu Mingbo, Zhao Feifang, Du Lei, Huang Deliang, Yang Shiming and Ma Lin, Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas, Current Cancer Drug Targets 2014; 14 (6) . https://dx.doi.org/10.2174/1568009614666140716115349
DOI https://dx.doi.org/10.2174/1568009614666140716115349 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report
Current Stem Cell Research & Therapy Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Recent Developments in Phytosterol Recovery from Oil Deodorizer Distillates
Current Nutrition & Food Science Carotid Ultrasound in One, Two and Three Dimensions
Vascular Disease Prevention (Discontinued) Causes of Impaired Fertility in Women with Polycystic Ovary Syndrome
Current Women`s Health Reviews Pathophysiology of Atherosclerotic Plaque Development
Cardiovascular & Hematological Agents in Medicinal Chemistry Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Iron-Induced Fibrin in Cardiovascular Disease
Current Neurovascular Research Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition HDL-C Levels and Cardiovascular Disease: More is not Always Better!
Recent Patents on Cardiovascular Drug Discovery Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Controversial Issues of Abortion License According to Religious and Jurisprudential Laws in Iran: A Systematic Review
Current Women`s Health Reviews Adiponectin - A Novel Anti-Atherogenic Factor in the Metabolic Syndrome: Mechanisms of Action and Therapeutic Potential
Vascular Disease Prevention (Discontinued)